NOT.DE - Novartis AG

XETRA - XETRA Delayed price. Currency in EUR
64.46
+0.62 (+0.97%)
As of 2:56PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close63.84
Open63.78
Bid64.36 x 76600
Ask64.40 x 36400
Day's range63.70 - 64.50
52-week range62.14 - 77.66
Volume5,752
Avg. volume13,260
Market cap163.629B
Beta0.64
PE ratio (TTM)18.90
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.39 (3.66%)
Ex-dividend date2018-03-06
1y target estN/A
  • Looking At Novartis AG (VTX:NOVN) From All Angles
    Simply Wall St.5 hours ago

    Looking At Novartis AG (VTX:NOVN) From All Angles

    Novartis AG (VTX:NOVN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of NOVN,Read More...

  • Don't Get Too Excited About PTC Therapeutics (Yet)
    Motley Fool2 days ago

    Don't Get Too Excited About PTC Therapeutics (Yet)

    PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.

  • Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
    Zacks3 days ago

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

  • S&P 500’s Top Losses: Why Biogen Declined
    Market Realist3 days ago

    S&P 500’s Top Losses: Why Biogen Declined

    The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen    

  • Novartis Announces Positive Data on CAR-T Therapy, Kymriah
    Zacks4 days ago

    Novartis Announces Positive Data on CAR-T Therapy, Kymriah

    Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.

  • Does Novartis AG (NYSE:NVS) Have A Place In Your Portfolio?
    Simply Wall St.7 days ago

    Does Novartis AG (NYSE:NVS) Have A Place In Your Portfolio?

    Over the past 10 years Novartis AG (NYSE:NVS) has returned an average of 4.00% per year from dividend payouts. The company is currently worth US$191.86B, and now yields roughly 3.71%.Read More...

  • The Wall Street Journal7 days ago

    [$$] Prosecutors Investigating Michael Cohen for Possible Illegal Lobbying

    Federal prosecutors in Manhattan are investigating whether Michael Cohen, the longtime personal lawyer for Donald Trump, illegally engaged in secret lobbying, people familiar with the investigation said, as part of the government’s broader probe into Mr. Cohen’s business dealings. In the course of that investigation, the prosecutors have contacted companies that hired Mr. Cohen as a consultant after Mr. Trump won the 2016 presidential election, including AT&T Inc. and Novartis AG, according to other people familiar with the matter.

  • MarketWatch8 days ago

    Is the future of therapy online? Swiss drug giant Novartis thinks so

    Can online access to mental health care improve the lives of patients with schizophrenia and multiple sclerosis? Swiss drug giant Novartis and its executive director of digital therapeutics, Joris Van Dam, say yes.

  • The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

  • Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
    Zacks14 days ago

    Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

    Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

  • The Wall Street Journal16 days ago

    [$$] The Novartis-Cohen Connection Explained

    Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it drew the attention of prosecutors at home.

  • Treasury Department Hasn't Responded to Cohen Probe Request
    Bloomberg16 days ago

    Treasury Department Hasn't Responded to Cohen Probe Request

    The U.S. Treasury Department has refused to respond to Senator Ron Wyden’s request for financial details related to payments that Swiss drugmaker Novartis AG made to Donald Trump’s lawyer Michael Cohen, a spokeswoman for the Democratic lawmaker said. Novartis is cooperating fully and provided “substantial” responses to the letter Wyden sent the company’s chief executive last month as part of a Senate Finance Committee review, according to an email from the Oregon senator’s office Wednesday.

  • Novartis Won't Be Investigated by Swiss Over Payments to Cohen
    Bloomberg16 days ago

    Novartis Won't Be Investigated by Swiss Over Payments to Cohen

    Switzerland’s top prosecutor won’t open criminal proceedings against Novartis AG over payments the Basel-based drugmaker made to Michael Cohen, the troubled lawyer for Donald Trump. After an in-depth analysis, the Office of the Attorney-General decided there was “insufficient suspicion to justify opening criminal proceedings” it said in a statement on Wednesday. The Swiss prosecutors said they consulted with the Basel Prosecutor’s Office in Novartis’s hometown, and failed to find sufficient grounds to proceed with charges into the allegations of bribery of a foreign public official or private individual.

  • Reuters16 days ago

    Swiss prosecutors will not pursue Novartis over Trump lawyer payments

    The Swiss attorney general's office (OAG) said on Wednesday it will not bring proceedings against Novartis in connection with $1.2 million in payments the Swiss drugmaker made to U.S. President Donald Trump's personal lawyer. The OAG had received a criminal complaint alleging bribery of foreign public officials by Novartis, which has said it struck a year-long contract with Trump lawyer Michael Cohen in 2017 to gain insights into the administration's thinking on healthcare issues. Novartis has since called the pact a mistake.

  • Swiss prosecutors will not pursue Novartis over Trump lawyer payments
    Reuters16 days ago

    Swiss prosecutors will not pursue Novartis over Trump lawyer payments

    The Swiss attorney general's office (OAG) said on Wednesday it will not bring proceedings against Novartis (NOVN.S) in connection with $1.2 million in payments the Swiss drugmaker made to U.S. President Donald Trump's personal lawyer. The OAG had received a criminal complaint alleging bribery of foreign public officials by Novartis, which has said it struck a year-long contract with Trump lawyer Michael Cohen in 2017 to gain insights into the administration's thinking on healthcare issues. Novartis has since called the pact a mistake.

  • Novartis Announces Positive Data on Kisqali and Tasigna
    Zacks18 days ago

    Novartis Announces Positive Data on Kisqali and Tasigna

    Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO.

  • How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
    Investor's Business Daily21 days ago

    How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales

    Novartis is one step closer to taking a bite out of AbbVie's blockbuster arthritis drug after a European committee recommended officials approve its Humira biosimilar on Friday.

  • Reuters - UK Focus21 days ago

    Novartis readies anti-sexism message for migraine drug

    With (Other OTC: WWTH - news) women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. The injectable monoclonal antibody that Novartis has developed with Amgen (NasdaqGS: AMGN - news) won approval in the United States this month and on Friday bagged a recommendation from a key European panel, clearing the way for likely approval on the continent. Novartis is also considering new pricing models for Aimovig.

  • Reuters21 days ago

    Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

    Novartis's (NOVN.S) generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's (ABBV.N) Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for marketing authorisation of Novartis's proposed biosimilar adalimumab. The European Commission nearly always follows the CHMP recommendation.

  • Reuters - UK Focus21 days ago

    Novartis wins key European panel's thumbs-up for migraine drug

    Novartis (IOB: 0QLR.IL - news) 's new migraine drug Aimovig won a key recommendation from a key European panel on Friday, helping open the way for potential sales before the end of the year for a medicine the Swiss drugmaker is counting on to boost growth. After receiving the nod from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) the drug for treating migraine headaches in adults still needs approval by the European Commission, but it usually follows the CHMP recommendation. The medicine, also called erenumab or AMG334, is the first in a new class of treatments designed to prevent migraine by interfering with calcitonin gene-related peptide (CGRP), which is involved in the processes that kick off the severe headaches, such as dilation of blood vessels in the brain.

  • The Wall Street Journal23 days ago

    [$$] Novartis Drug Promacta Gets FDA Priority Review for First-Line SAA

    AG (NOVN.EB) said Wednesday that the U.S. Food and Drug Administration granted priority review designation to drug Promacta for first-line treatment of severe aplastic anemia, or SAA. The priority review is based on data that shows that 52% of treatment-naive SAA patients achieved complete response at six months when treated with Promacta in combination with standard immunosuppressive therapy, Novartis said. This represents an increase of 35% compared with patients treated with the standard treatment alone, it added.

  • The Wall Street Journallast month

    [$$] Cohen Probe Trips Up Bridgewater Plan for Board

    Bridgewater Associates was close to bringing on Joseph Jimenez, the former chief executive of Novartis AG, but may back off in the wake of public revelations about his role in payments to President Donald Trump’s personal attorney, people familiar with the matter said. Mr. Jimenez has been thrust into the international spotlight in recent weeks for directing $1.2 million to Mr. Trump’s attorney, Michael Cohen, who is under federal investigation.

  • The Wall Street Journallast month

    New Migraine Drugs Offer Hope to Sufferers

    Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zackslast month

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • MarketWatchlast month

    FDA approves anti-migraine drug from Novartis, Amgen

    Shares of drugmakers Amgen Inc. and Novartis AG rose in after-hours trading Thursday after jointly announcing FDA approval of Aimovig, a first-of-its-kind treatment for migraines. In a statement, Novartis said the Federal Drug Administration approved Aimovig's use for the preventive treatment of migraines in adults. "Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine," Novartis Chief Executive Paul Hudson said in the statement.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes